Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
In connection with the European Immunization Week, ECDC releases data indicating an increase in cases of vaccine-preventable diseases such as measles and pertussis, after decreased levels during the COVID-19 pandemic.
ECDC provides support to EU/EEA countries in monitoring their progress towards the hepatitis elimination targets and has just published a report based on the second data collection.
Approximately four in five people living with hepatitis B and three out of four people with hepatitis C infection across the European Union and European Economic Area (EU/EEA) and the UK have not yet been diagnosed. This is a major obstacle on the way towards the Sustainable Development Goal (SDG) for health in 2030 as highlighted by ECDC on occasion of World Hepatitis Day.
The first report monitoring the progress towards the elimination of hepatitis B and C across European Union (EU) and European Economic Area (EEA) countries has been published by ECDC.
The latest ECDC mosquito maps show new information about the geographical distribution of Aedes albopictus and Aedes aegypti, invasive mosquitoes which can transmit diseases such as dengue and Zika, in Europe.
The goal for 2030: a world free of hepatitis. Currently, Europe records around 57 000 newly diagnosed acute and chronic cases of hepatitis B and C each year.
The study design and analysis controlled for influence of potentially confounding trends, such as improvement of day-care carriage and decreasing prevalence of smoking during the study period.